Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 3/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 7/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4914684 | 0.96 | NR1I2 (0.44) | ADRB3NR1I2HPGDALDH1A1KMT2A | |
| SCHEMBL1379764 | 0.96 | NR1I2 (0.44) | ADRB3NR1I2HPGDALDH1A1KMT2A | |
| Trifluoroacetic Acid SCHEMBL4645770 | 0.94 | ADRB3 (0.42) | ADRB3NR1I2HPGDKEAP1NFE2L2 | |
| Trifluoroacetic Acid SCHEMBL4910752 | 0.94 | ADRB3 (0.41) | ADRB3NR1I2HPGDALDH1A1KMT2A | |
| SCHEMBL4908168 | 0.91 | ADRB3 (0.42) | ADRB3NR1I2HPGDALDH1A1KMT2A | |
| SCHEMBL4915375 | 0.90 | ADRB3 (0.43) | ADRB3NR1I2HPGDKEAP1NFE2L2 | |
| SCHEMBL4915362 | 0.90 | ADRB3 (0.43) | ADRB3NR1I2HPGDKEAP1NFE2L2 | |
| Trifluoroacetic Acid SCHEMBL4908055 | 0.90 | ADRB3 (0.46) | ADRB3NR1I2HPGDALDH1A1KMT2A | |
| SCHEMBL4908069 | 0.90 | NR1I2 (0.43) | ADRB3NR1I2HPGDALDH1A1KMT2A | |
| SCHEMBL4917492 | 0.90 | NR1I2 (0.43) | ADRB3NR1I2HPGDALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943229-A1 | BENZIMIDAZOLE DERIVATIVES FOR USE AS BETA-3 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-01 | — | — | US | disclosed |
| US-20080021042-A1 | Composition For Controlling Neuropathic Pain | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
| WO-2007048842-A1 | BENZIMIDAZOLE DERIVATIVES FOR USE AS BETA-3 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | ADRB3 2/4885NR1I2 307/4885HPGD 1119/4885 |
| US-20080021042-A1 | Composition For Controlling Neuropathic Pain | GAP43, SCN10A, SCN2A | ADRB3 379/4885NR1I2 2959/4885HPGD 2071/4885 |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | ADRB3, ADRB1, ADRA1B | ADRB3 1/4885NR1I2 103/4885HPGD 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.